Testing NalIriFOx as first treatment for metastatic pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a drug combination called NalIriFOx as the first treatment for people with pancreatic cancer that has spread. The goal is to see if it is safe and works well over the long term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body (metastatic).
- You are about to start your very first treatment for this cancer with a combination of drugs called NalIriFOx (as decided by your doctor).
- You are willing to sign a consent form saying you understand and agree to be in the study.
- You have not had chemotherapy or radiation before or after surgery in the last 6 months.
- You have never been treated with liposomal irinotecan (a drug also called Onivyde).
- You have not previously received any chemotherapy or other cancer treatment for the spread of your pancreatic cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) as a first treatment for people with locally advanced pancreatic cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests a new drug combination (NALIRIFOX plus immunotherapy) followed by radiation, compared to NALIRIFOX alone, as a way to shrink pancreatic tumors that haven't spread and make them removable. It's for people who haven't had any previous cancer treatment.
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) is effective as a first treatment for pancreatic cancer that has spread. It also studies how gut bacteria affect the success of a second treatment with gemcitabine and paclitaxel. The goal is to find better ways to treat pancreatic cancer by personalizing therapy.
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.